Published in Medical Letter on the CDC and FDA, September 12th, 2004
The U.S.FDA's pre-IND meeting programs are designed to provide sponsors with advance guidance and input on drug development programs. TheraQuest has also completed consultations on TQ-1011 with the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and the Canadian Therapeutic Products Directorate (TPD).
The treatment of post-surgical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.